uniQure N.V. (QURE) - Stock Analysis
Last updated: Jun 7, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
uniQureâs Phase I/II Huntingtonâs gene therapy trial showed a 75% slowing of progression, triggering a 250% price surge and near five-year high. Strong FDA alignment for BLA filing and robust capital provide near-term growth catalysts despite technical overbought conditions and dilution risk.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Cash Cushion ⢠Operating Losses ⢠High Leverage QURE has ample cash and strong gross margins, but persistent operating losses, negative free cash flow, high leverage, and a rich sales multiple make the equity a high-risk, liquidity-dependent story.
Price Behavior
Key Price Behavior Insights: ⢠Breakout Attempt ⢠Sharp Pullback ⢠Key Support Support Level: $24.20â$24.90 Resistance Level: $28.50â$30.00 Over the last month, QURE trended higher and briefly broke into the high-$20s, but the sharp drop from $29.88 to $26.45 shows fading momentum and leaves $24.20â$24.90 as key support and $28.50â$30.00 as resistance.
Sentiment & News
Key News Insights: ⢠Regulatory uncertainty ⢠UK filing ⢠Pipeline optionality QURE remains driven by AMT-130 regulatory uncertainty, with a potential UK filing offset by lingering FDA demands for a likely Phase 3 trial and a wide valuation range.
AI Summary
QURE is now best viewed as a cash-backed but highly speculative AMT-130 regulatory trade, where the real upside depends on the FDA not forcing a new Phase 3 trial and the legal overhang easing enough to support a rerating before the market loses patience.
Description
uniQure N.V. is a gene therapy company developing treatments for genetic and other severe diseases. Its lead program, etranacogene dezaparvovec (AMT-061), is in the Phase III HOPE-B trial for hemophilia B, and the broader pipeline includes clinical and preclinical candidates targeting central nervous system and neuromuscular disorders such as Huntingtonâs disease, Parkinsonâs disease, temporal lobe epilepsy, ALS and forms of Alzheimerâs, as well as earlier-stage hemophilia approaches. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 29 | Oct 6 | QURE | uniQure N.V. | uniQureâs Phase I/II Huntingtonâs gene therapy trial showed a 75% slowing of progression, triggering a 250% price surge and near five-year high. Strong FDA alignment for BLA filing and robust capital provide near-term growth catalysts despite technical overbought conditions and dilution risk. | Closed | -10.9% |